Brainstorm Cell Therapeutics Inc. (BCLI)
Fuera de horario:
Brainstorm Cell Therapeutics Inc.
1325 Avenue of Americas
28th Floor
New York, NY 10019
United States
201 488 0460
https://www.brainstorm-cell.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 29
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Chaim Lebovits | President & Co-CEO | 878.78k | N/D | 1971 |
| Dr. Stacy R. Lindborg Ph.D. | Co-Chief Executive Officer | 751.08k | N/D | 1971 |
| Dr. Irit Arbel DSc, Ph.D. | Co-Founder & Independent Vice Chair of the Board | N/D | N/D | 1960 |
| Ms. Alla Patlis CPA, M.B.A. | Interim CFO & Controller | 130.92k | N/D | 1987 |
| Mr. Uri Yablonka | Executive VP, Chief Business Officer, Secretary & Director | 247.06k | N/D | 1977 |
| Dr. Daniel Offen Ph.D. | Chief Scientific Advisor | N/D | N/D | N/D |
| Ms. Mary Kay Turner | Senior Vice President of Patient Advocacy & Government Affairs | N/D | N/D | N/D |
| Dr. Ibrahim Dagher M.D. | Executive VP & Chief Medical Officer | N/D | N/D | 1969 |
Descripción
Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
Gestión corporativa
La calificación ISS Governance QuickScore de Brainstorm Cell Therapeutics Inc. a partir del 29 de abril de 2024 es 4. Las puntuaciones principales son Auditoría: 8; Junta: 4; Derechos del accionista: 2; Compensación: 7.
